Condition | Absorption Rate | ka |
---|---|---|
% of dose | h-1 | |
[14C]Bepotastine (1 μM) | 63.0 ± 2.4 | 1.98 ± 0.12 (1.00) |
[14C]Bepotastine (20 mM) | 74.2 ± 5.9a | 2.84 ± 0.53 (1.43) |
[14C]Bepotastine (1 μM) + diphenhydramine (20 mM) | 57.1 ± 3.7 | 1.71 ± 0.18 (0.86) |
[14C]Bepotastine (1 μM) + cyclosporin A (50 μM) | 81.5 ± 2.1a | 3.40 ± 0.22a (1.71) |
[14C]Bepotastine (1 μM) + verapamil (10 mM) | 72.4 ± 1.1a | 2.58 ± 0.08 (1.30) |
Fexofenadine (370 μM) | 8.5 ± 0.3 | 0.18 ± 0.01 (1.00) |
Fexofenadine (370 μM) + cyclosporin A (50 μM) | 29.9 ± 7.3a | 0.73 ± 0.22a (4.12) |
Fexofenadine (370 μM) + verapamil (10 mM) | 24.9 ± 4.9a | 0.58 ± 0.13a (3.26) |
[14C]Mannitol (1 μM) | 4.4 ± 1.2 | 0.09 ± 0.02 |
↵ a Statistical difference of the absorption rate (% of dose) and the apparent absorption rate constant, ka, in the presence of excessive bepotastine and several drugs including P-gp inhibitors was assessed by Student's t test (P < 0.05).